(Q42610796)

English

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

scientific article published on November 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole (English)

1 reference

Europe PubMed Central

3 November 2017

3

object named as

Pluzanska A

1 reference

Europe PubMed Central

3 November 2017

author name string

Rose C

1

1 reference

Europe PubMed Central

3 November 2017

Vtoraya O

2

1 reference

Europe PubMed Central

3 November 2017

Davidson N

4

1 reference

Europe PubMed Central

3 November 2017

Gershanovich M

5

1 reference

Europe PubMed Central

3 November 2017

Thomas R

6

1 reference

Europe PubMed Central

3 November 2017

Johnson S

7

1 reference

Europe PubMed Central

3 November 2017

Caicedo JJ

8

1 reference

Europe PubMed Central

3 November 2017

Gervasio H

9

1 reference

Europe PubMed Central

3 November 2017

Manikhas G

10

1 reference

Europe PubMed Central

3 November 2017

Ben Ayed F

11

1 reference

Europe PubMed Central

3 November 2017

Burdette-Radoux S

12

1 reference

Europe PubMed Central

3 November 2017

Chaudri-Ross HA

13

1 reference

Europe PubMed Central

3 November 2017

Lang R

14

1 reference

Europe PubMed Central

3 November 2017

publication date

1 November 2003

1 reference

Europe PubMed Central

3 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

3 November 2017

39

1 reference

Europe PubMed Central

3 November 2017

16

1 reference

Europe PubMed Central

3 November 2017

2318-2327

1 reference

Europe PubMed Central

3 November 2017

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of aromatase inhibitors in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New endocrine drugs for treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Stepwise estrogen suppression manipulating the estrostat

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Lessons from the use of aromatase inhibitors in the neoadjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900630-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00630-0

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42610796&oldid=2124492946"